Kirk Russ
Gastroenterology · Birmingham, ALNPI 1083971121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,055 of the $37,575 with a category attached, or 61.4%. 17 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 52.1% of the total. Reporting peaked in 2024 at $20,164 and has fallen 83.5% since, to $3,330 in 2025. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $560.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- Pfizer$8K
- E.r. Squibb & Sons, L.L.C.$6K
- Celltrion USA Inc.$3K
- Olympus America Inc.$352
- AbbVie$320
- plus $946 from 11 others
Across 16 payments — averaging $6294.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$58K
- Janssen Research & Development, LLC$39K
- AbbVie$4K
What the payments were for
- Consulting fees$11,80831%
- Speaking & faculty fees$23,05561%
- Travel & lodging$1450%
- Food & beverage$2,1136%
- Education$4541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $19,580 |
| Pfizer | 5 | $7,674 |
| E.r. Squibb & Sons, L.L.C. | 5 | $5,567 |
| Celltrion USA Inc. | 13 | $3,137 |
| Olympus America Inc. | 5 | $352 |
| AbbVie | 6 | $320 |
| Bristol Myers Squibb | 8 | $311 |
| Janssen Scientific Affairs, LLC | 2 | $244 |
| Johnson & Johnson | 5 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Exact Sciences | 1 | $46 |
| Conmed Corporation | 1 | $40 |
| AstraZeneca | 2 | $34 |
| Bayer | 2 | $32 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Entyvio$19,580
- XELJANZ$7,200
- ZYMFENTRA$2,818
- STELARA$244
- Single Use Repositionable Clip$120
- EVIS EXERA III COLONOVIDEOSCOPE$106
- EVIS EUS ENDOSCOPIC ULTRASOUND CENTER$106
How this compares
$37,575 in reported general payments places this provider in the 90th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 109 | $2,907,966 |
| GattexTeduglutide | 26 | $1,721,893 |
| Skyrizi On-BodyRisankizumab-Rzaa | 46 | $909,699 |
| Humira(Cf) PenAdalimumab | 48 | $618,679 |
| Humira PenAdalimumab | 43 | $410,631 |
| RinvoqUpadacitinib | 43 | $346,421 |
| Entyvio PenVedolizumab | 36 | $220,835 |
| SkyriziRisankizumab-Rzaa | 14 | $133,135 |
| EntyvioVedolizumab | 14 | $114,733 |
| InflectraInfliximab-Dyyb | 13 | $97,428 |
| Xeljanz XrTofacitinib Citrate | 11 | $59,550 |
| ViberziEluxadoline | 34 | $49,655 |
| Mesalamine | 56 | $38,875 |
| Octreotide Acetate | 12 | $5,709 |
| Colestipol Hcl | 32 | $5,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $120 | $2,907,966109 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Entyvio | $19,580 | $1,836,62640 claims |
| AbbVieRinvoq, Skyrizi, Viberzi | $320 | $529,21091 claims |
| PfizerInflectra | $7,674 | $97,42813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Birmingham
- Robert ShafferBirmingham$1M
- Mukul MehraBirmingham$193K
- Meagan GrayBirmingham$113K
- David SteeleBirmingham$47K
- Kenneth SigmanBirmingham$34K
- Shajan PeterBirmingham$31K
- Ali AhmedBirmingham$27K
- Swaroop VittaBirmingham$15K
- Rajat ParikhBirmingham$14K
- James CallawayBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.